ArticleMethods in molecular biology (Clifton, N.J.)2026
RNA-Seq and XAI Can be Used as Tools to Aid Pathologists in the Process of Cancer Diagnosis.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA sequencing (RNA-Seq) is an advanced technique that enables the comprehensive analysis of gene expression and the transcriptome in biological samples with exceptional precision and scalability. Leveraging platforms like Illumina, PacBio, and Oxford Nanopore, RNA-Seq has revolutionized cancer research by identifying genes, isoforms, and genetic variants. When combined with bioinformatics tools, it allows the detection of gene expression signatures, alternative splicing events, and profiles of non-coding RNAs. Furthermore, single-cell analysis provides insights into tumor heterogeneity, enhancing diagnostics, prognostics, and the development of personalized therapies.Artificial intelligence (AI), particularly explainable AI (XAI), plays a pivotal role in transcriptomic data analysis. Interpretable models, such as regression analyses or decision trees, and post-hoc techniques like LIME and SHAP, improve the reliability and usability of findings by identifying key genes for clinical decision-making. These tools integrate seamlessly with high-resolution single-cell and three-dimensional analyses, exploring intratumoral heterogeneity and cellular signaling pathways.Addressing the heterogeneity of common cancers demands the integration of sequencing technologies and AI. The combination of short- and long-read RNA-Seq enables the identification of isoforms and splicing events critical to cancer biology. Together, these technologies and approaches optimize diagnostic and therapeutic strategies, paving the way for personalized treatments by detecting and characterizing genetic alterations and their impact on the tumor microenvironment.
Indexed as
Identifiers
42426469What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.